

# Nevada Preferred Drug List (PDL) Information

---

Effective July 20, 2022

PDL drug coverage information can be found at <https://nevadamedicaid.magellanrx.com/home>.

- Nevada Medicaid's PDL only includes select drug classes
- PDL Preferred Products do not require Prior Authorization (PA) unless subject to additional clinical criteria (indicated by <sup>PA</sup> next to drug name)
- Non-Preferred Products require PA for approval
- Drugs not on the PDL are subject to Nevada's mandatory generic substitution requirements

PA requests may be submitted by electronic PA (ePA), fax, or phone:

- **ePA:** <https://www.covermy meds.com/main/prior-authorization-forms/magellan-rx/>
- **Fax:** 844-347-3202
  - PA fax forms: <https://nevadamedicaid.magellanrx.com/home>
- **Phone:** 800-695-5526

## KEY

cap = capsule

ER = extended release

inj = injection

IR = immediate release

nebs = nebulizer

ODT = oral disintegrating tablet

oint = ointment

PA = Prior Authorization

QL = Quantity Limit

soln = solution

supp = suppository

susp = suspension

tab = tablet

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## Table of Contents

|   |           |
|---|-----------|
| <b>Analgesics</b> .....   | <b>7</b>  |
| Miscellaneous Analgesics .....  | 7         |
| <i>Neuropathic Pain/Fibromyalgia Agents</i> .....                               | 7         |
| <i>Tramadol and Related Drugs</i> .....   | 7         |
| Opiate Agonists.....  | 7         |
| Opiate Agonists – Abuse Deterrents.....   | 7         |
| Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) – Oral.....                      | 8         |
| <b>Antihistamines</b> .....   | <b>8</b>  |
| H1 Blockers – Non-Sedating .....  | 8         |
| <b>Anti-Infective Agents</b> .....  | <b>9</b>  |
| Aminoglycosides .....   | 9         |
| <i>Inhaled Aminoglycosides</i> .....  | 9         |
| Antivirals.....   | 9         |
| <i>Alpha Interferons</i> .....  | 9         |
| <i>Anti-hepatitis Agents – Polymerase Inhibitors/Combination Products</i> ..... | 9         |
| <i>Anti-hepatitis Agents – Ribavirin</i> .....                                  | 9         |
| <i>Anti-herpetic Agents</i> .....   | 9         |
| <i>Influenza Agents</i> .....   | 9         |
| Cephalosporins .....  | 9         |
| <i>Second-Generation Cephalosporins</i> .....                                   | 9         |
| <i>Third-Generation Cephalosporins</i> .....                                    | 9         |
| Macrolides.....   | 10        |
| Quinolones .....  | 10        |
| <i>Quinolones – 2nd Generation</i> .....  | 10        |
| <i>Quinolones – 3rd Generation</i> .....  | 10        |
| <b>Autonomic Agents</b> .....   | <b>10</b> |
| Sympathomimetics.....   | 10        |
| <i>Self-Injectable Epinephrine</i> .....  | 10        |
| <b>Biologic Response Modifiers</b> .....  | <b>11</b> |
| Immunomodulators.....   | 11        |
| <i>Targeted Immunomodulator</i> .....   | 11        |
| Multiple Sclerosis Agents.....  | 11        |
| <i>Injectable</i> .....   | 11        |
| <i>Oral</i> .....   | 11        |
| <i>Specific Symptomatic Treatment</i> .....                                     | 11        |
| <b>Cardiovascular Agents</b> .....  | <b>12</b> |
| Antihypertensive Agents .....   | 12        |
| <i>Angiotensin II Receptor Antagonists</i> .....                                | 12        |
| <i>Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)</i> .....          | 12        |
| <i>Beta-Blockers</i> .....  | 12        |
| <i>Calcium-Channel Blockers</i> .....   | 13        |
| <i>Vasodilators – Inhaled</i> .....   | 13        |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

|  |           |
|--|-----------|
| <i>Vasodilators – Oral</i> .....   | 13        |
| Antilipemics .....   | 13        |
| <i>Bile Acid Sequestrants</i> .....  | 13        |
| <i>Cholesterol Absorption Inhibitors</i> .....   | 13        |
| <i>Fibric Acid Derivatives</i> .....   | 13        |
| <i>HMG-CoA Reductase Inhibitors (Statins)</i> .....  | 14        |
| <i>Niacin Agents</i> .....   | 14        |
| <i>Omega-3 Fatty Acids</i> .....   | 14        |
| <i>PCSK9 Inhibitors</i> .....  | 14        |
| Miscellaneous Heart Failure Agents .....   | 14        |
| <b>Dermatological Agents</b> .....   | <b>14</b> |
| Antipsoriatic Agents .....   | 14        |
| Topical Analgesics.....  | 15        |
| Topical Anti-infectives .....  | 15        |
| <i>Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products</i> ..... | 15        |
| <i>Impetigo Agents: Topical</i> .....  | 15        |
| <i>Topical Antivirals</i> .....  | 15        |
| <i>Topical Scabicides</i> .....  | 15        |
| Topical Anti-inflammatory Agents .....   | 16        |
| <i>Immunomodulators: Topical</i> .....   | 16        |
| Topical Antineoplastics .....  | 16        |
| <i>Topical Retinoids</i> .....   | 16        |
| <b>Electrolytic and Renal Agents</b> .....   | <b>16</b> |
| Phosphate Binding Agents .....   | 16        |
| Potassium Removing Agents .....  | 16        |
| <b>Gastrointestinal Agents</b> .....   | <b>17</b> |
| Antiemetics.....   | 17        |
| <i>Pregnancy-induced Nausea and Vomiting Treatment</i> .....                               | 17        |
| <i>Serotonin-receptor antagonists/Combo</i> .....  | 17        |
| Antiulcer Agents .....   | 17        |
| <i>H2 Blockers</i> .....   | 17        |
| <i>Proton Pump Inhibitors (PPIs)</i> .....   | 17        |
| Functional Gastrointestinal Disorder Drugs .....   | 17        |
| Gastrointestinal Anti-inflammatory Agents .....  | 18        |
| Gastrointestinal Enzymes .....   | 18        |
| <b>Genitourinary Agents</b> .....  | <b>18</b> |
| Benign Prostatic Hyperplasia (BPH) Agents .....  | 18        |
| <i>5-Alpha Reductase Inhibitors</i> .....  | 18        |
| <i>Alpha-Blockers</i> .....  | 18        |
| Bladder Antispasmodics .....   | 18        |
| <b>Hematological Agents</b> .....  | <b>19</b> |
| Anticoagulants .....   | 19        |
| <i>Oral</i> .....  | 19        |
| <i>Injectable</i> .....  | 19        |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

|  |           |
|--|-----------|
| Erythropoiesis-Stimulating Agents.....   | 19        |
| Platelet Inhibitors .....  | 19        |
| <b>Hormones and Hormone Modifiers .....</b>                                      | <b>20</b> |
| Androgens .....  | 20        |
| Antidiabetic Agents .....  | 20        |
| <i>Alpha-Glucosidase Inhibitors/Amylin analogs/Misc</i> .....                    | 20        |
| <i>Biguanides</i> .....  | 20        |
| <i>Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin</i> .....   | 20        |
| <i>Incretin Mimetics and Combinations</i> .....                                  | 20        |
| <i>Meglitinides</i> .....  | 20        |
| <i>Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations</i> ..... | 20        |
| <i>Sulfonylureas</i> .....   | 21        |
| <i>Thiazolidinediones and Combinations</i> .....                                 | 21        |
| Anti-Hypoglycemic Agents.....  | 21        |
| Insulins.....  | 21        |
| <i>Rapid Acting Insulins</i> .....   | 21        |
| <i>Short-Intermediate Acting Insulins</i> .....                                  | 21        |
| <i>Long-Acting Insulins</i> .....  | 21        |
| <i>Pre-Mixed Insulin Combinations</i> .....                                      | 21        |
| Pituitary Hormones.....  | 22        |
| <i>Growth Hormone Modifiers</i> .....  | 22        |
| Progestins for Cachexia .....  | 22        |
| <b>Monoclonal Antibodies for the Treatment of Respiratory Conditions.....</b>    | <b>22</b> |
| <b>Musculoskeletal Agents .....</b>  | <b>22</b> |
| Antigout Agents .....  | 22        |
| Bone Resorption Inhibitors .....   | 22        |
| <i>Bisphosphonates</i> .....   | 22        |
| <i>Nasal Calcitonins</i> .....   | 22        |
| Restless Leg Syndrome Agents .....   | 23        |
| Skeletal Muscle Relaxants.....   | 23        |
| <b>Neurological Agents .....</b>   | <b>23</b> |
| Alzheimer’s Agents .....   | 23        |
| <i>Cholinesterase Inhibitors</i> .....   | 23        |
| <i>NMDA Receptor Antagonist</i> .....  | 23        |
| Anticonvulsants .....  | 24        |
| <i>Barbiturates</i> .....  | 24        |
| <i>Benzodiazepines</i> .....   | 25        |
| <i>Hydantoins</i> .....  | 25        |
| Anti-Migraine Agents.....  | 25        |
| <i>Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists</i> .....         | 25        |
| <i>Serotonin-Receptor Agonists (Triptans)</i> .....                              | 25        |
| Antiparkinsonian Agents.....   | 26        |
| <i>Dopamine Precursors</i> .....   | 26        |
| <i>Non-Ergot Dopamine Agonists</i> .....   | 26        |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

|  |           |
|--|-----------|
| Movement Disorders.....  | 26        |
| <b>Ophthalmic Agents.....</b>  | <b>26</b> |
| Antiglaucoma Agents.....   | 26        |
| Ophthalmic Antihistamines .....  | 26        |
| Ophthalmic Anti-infectives .....   | 27        |
| <i>Ophthalmic Macrolides</i> .....   | 27        |
| <i>Ophthalmic Quinolones</i> .....   | 27        |
| Ophthalmic Anti-infective/Anti-inflammatory Combinations.....                          | 27        |
| Ophthalmic Anti-inflammatory Agents.....   | 27        |
| <i>Ophthalmic Corticosteroids</i> .....  | 27        |
| <i>Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</i> .....                  | 27        |
| Ophthalmics for Dry Eye Disease.....   | 27        |
| <b>Otic Agents .....</b>   | <b>28</b> |
| Otic Anti-infectives .....   | 28        |
| <i>Otic Quinolones</i> .....   | 28        |
| <b>Psychotropic Agents.....</b>  | <b>28</b> |
| ADHD Agents .....  | 28        |
| Antidepressants.....   | 29        |
| <i>Other</i> .....   | 29        |
| <i>Selective Serotonin Reuptake Inhibitors (SSRIs)</i> .....                           | 29        |
| Antipsychotics.....  | 29        |
| <i>Atypical Antipsychotics – Oral/Topical</i> .....                                    | 29        |
| <i>Atypical Antipsychotics – Long Acting Injectable</i> .....                          | 30        |
| Anxiolytics, Sedatives, and Hypnotics.....   | 30        |
| Psychostimulants.....  | 30        |
| <i>Narcolepsy Agents</i> .....   | 30        |
| <b>Respiratory Agents.....</b>   | <b>30</b> |
| Nasal Antihistamines .....   | 30        |
| Respiratory Anti-inflammatory Agents.....  | 30        |
| <i>Leukotriene Receptor Antagonists</i> .....  | 30        |
| Nasal Corticosteroids.....   | 31        |
| <i>Phosphodiesterase Type 4 Inhibitors</i> .....                                       | 31        |
| Long-Acting Maintenance Therapy.....   | 31        |
| <i>Inhaled Glucocorticoids</i> .....   | 31        |
| <i>Glucocorticoids/Long-Acting Beta-2 Adrenergic (LABA) Combination Products</i> ..... | 31        |
| <i>Long-Acting Beta Adrenergics (LABA)</i> .....                                       | 31        |
| <i>Anticholinergics and Combination Products</i> .....                                 | 31        |
| <i>Short-Acting Beta Adrenergic (SABA)</i> .....                                       | 32        |
| <i>Ipratropium and Combinations</i> .....  | 32        |
| <b>Toxicology Agents .....</b>   | <b>32</b> |
| Antidotes .....  | 32        |
| <i>Opiate Antagonists</i> .....  | 32        |
| Substance Abuse Agents.....  | 32        |

**Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)**

Effective July 20, 2022

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**ANALGESICS**

| Preferred Products   | Non Preferred Products  | Coverage Limitations  |
|--|---|---|
| <b>Miscellaneous Analgesics</b>  |   |   |
| <b>Neuropathic Pain/Fibromyalgia Agents</b>  |   |   |
| duloxetine<br>gabapentin<br>Lidoderm® PA<br>Lyrica® IR<br>Neurontin®<br>Savella® PA*                         | Cymbalta®<br>Gralise®<br>Horizant®<br>lidocaine patch<br>Lyrica® CR<br>pregabalin IR<br>pregabalin CR<br>Qutenza®   | * No PA required for drugs in this class if ICD-10 – M79.1; M60.0-M60.9, M61.1 (fibromyalgia) |
| <b>Tramadol and Related Drugs</b>  |   |   |
| tramadol IR<br>tramadol/APAP   | ConZip®<br>Nucynta®<br>tramadol ER<br>Ultracet®<br>Ultram®  |   |
| <b>Opiate Agonists</b>   |   |   |
| Butrans®<br>fentanyl patch QL PA<br>morphine sulfate SA tab (all generic extended release) QL<br>Nucynta® ER | Avinza® QL<br>buprenorphine patch<br>Dolophine®<br>Duragesic® patches QL<br>Exalgo®<br>hydrocodone bitartrate ER<br>Kadian® QL<br>methadone<br>Methadose®<br>MS Contin® QL<br>Opana® ER<br>oxycodone SR QL<br>oxymorphone SR<br>Xartemis® XR QL<br>Zohydro® ER QL |   |
| <b>Opiate Agonists – Abuse Deterrents</b>  |   |   |
| Xtampza® ER  | hydrocodone bitartrate ER<br>Hysingla® ER<br>Oxycontin® QL  |   |

## Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

### ANALGESICS

| Preferred Products  | Non Preferred Products  | Coverage Limitations |
|---|---|----------------------|
| <b>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) – Oral</b>  |   |                      |
| celecoxib cap <sup>QL</sup><br>diclofenac potassium<br>diclofenac sodium IR tab<br>diclofenac sodium ER tab<br>ibuprofen susp<br>ibuprofen tab<br>indomethacin IR cap<br>ketorolac tab <sup>QL PA</sup><br>meloxicam tab<br>nabumetone tab<br>naproxen susp<br>naproxen tab<br>naproxen DR tab<br>piroxicam cap<br>sulindac tab | Cambia® powder<br>diclofenac sodium tab ER<br>diclofenac w/ misoprostol tab<br>Duexis® tab<br>etodolac IR cap<br>etodolac IR tab<br>etodolac ER tab<br>indomethacin ER cap<br>ketoprofen cap<br>mefenamic cap<br>meloxicam susp<br>Naprelan® CR tab<br>naproxen CR tab<br>naproxen ER tab<br>oxaprozin tab<br>Sprix® spray<br>Vimovo® tab<br>Zipsor® cap<br>Zorvolex® cap |                      |

### ANTIHISTAMINES

| Preferred Products   | Non Preferred Products   | Prior Authorization Criteria   |
|--|--|--|
| <b>H1 Blockers – Non-Sedating</b>                                      |  |  |
| cetirizine OTC<br>levocetirizine<br>loratadine D OTC<br>loratadine OTC | Allegra®<br>cetirizine D OTC<br>Clarinex®<br>Clarinex-D®<br>Claritin®<br>desloratadine<br>fexofenadine<br>Xyzal® | A two-week trial of one preferred drug is required before a non-preferred drug will be authorized. |



# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## ANTI-INFECTIVE AGENTS

| Preferred Products  | Non Preferred Products  | Prior Authorization Criteria |
|---|---|------------------------------|
| <b>Aminoglycosides</b>  |   |                              |
| <b>Inhaled Aminoglycosides</b>  |   |                              |
| Bethkis®<br>Kitabis® Pak<br>tobramycin 300mg/5ml nebulizer  | Tobi Podhaler®<br>tobramycin 300mg/4ml nebulizer  |                              |
| <b>Antivirals</b>   |   |                              |
| <b>Alpha Interferons</b>  |   |                              |
| Pegasys®<br>Pegasys® convenient pack<br>Peg-Intron® and Redipen   |   |                              |
| <b>Anti-hepatitis Agents – Polymerase Inhibitors/Combination Products</b>   |   |                              |
| Epclusa® <sup>PA</sup><br>Harvoni® <sup>QL PA</sup><br>ledipasvir/sofosbuvir <sup>QL PA</sup><br>Mavyret® <sup>PA</sup><br>sofosbuvir/velpatasvir <sup>PA</sup> | Sovaldi® <sup>QL PA</sup><br>Viekira® Pak <sup>PA</sup><br>Vosevi® <sup>PA</sup><br>Zepatier® <sup>PA</sup> |                              |
| <b>Anti-hepatitis Agents – Ribavirin</b>  |   |                              |
| ribavirin   |   |                              |
| <b>Anti-herpetic Agents</b>   |   |                              |
| acyclovir<br>famciclovir<br>valacyclovir  |   |                              |
| <b>Influenza Agents</b>   |   |                              |
| amantadine<br>oseltamivir cap/susp<br>rimantadine<br>Relenza®   | Rapivab®<br>Tamiflu®<br>Xofluza®  |                              |
| <b>Cephalosporins</b>   |   |                              |
| <b>Second-Generation Cephalosporins</b>   |   |                              |
| cefaclor cap and susp<br>cefaclor ER tab<br>cefuroxime tab and susp<br>cefprozil tab and susp   | Ceclor®<br>Ceclor® CD<br>Ceftin®<br>Cefzil®   |                              |
| <b>Third-Generation Cephalosporins</b>  |   |                              |
| cefdinir cap and susp <sup>PA</sup><br>cefepodoxime tab and susp <sup>PA</sup>  | cefixime cap and susp <sup>PA</sup><br>Suprax® <sup>PA</sup>  |                              |

## Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

### ANTI-INFECTIVE AGENTS

| Preferred Products   | Non Preferred Products  | Prior Authorization Criteria |
|--|-------------------------|------------------------------|
| <b>Macrolides</b>  |                         |                              |
| azithromycin tab/susp<br>clarithromycin tab/susp<br>clarithromycin XL<br>erythromycin base<br>erythromycin ethylsuccinate<br>Erythrocin® | Dificid®<br>Zithromax®  |                              |
| <b>Quinolones</b>  |                         |                              |
| <b>Quinolones – 2nd Generation</b>   |                         |                              |
| ciprofloxacin tabs <sup>PA</sup><br>Cipro® susp <sup>PA</sup>  | ofloxacin <sup>PA</sup> |                              |
| <b>Quinolones – 3rd Generation</b>   |                         |                              |
| levofloxacin <sup>PA</sup><br>moxifloxacin <sup>PA</sup>   | Avelox® <sup>PA</sup>   |                              |

### AUTONOMIC AGENTS

| Preferred Products                   | Non Preferred Products                            | Prior Authorization Criteria |
|--------------------------------------|---|------------------------------|
| <b>Sympathomimetics</b>              |   |                              |
| <b>Self-Injectable Epinephrine</b>   |   |                              |
| epinephrine auto inj<br>Epinephrine® | Adrenaclick® <sup>QL</sup><br>Auvi-Q®<br>Symjepi® |                              |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**BIOLOGIC RESPONSE MODIFIERS**

| Preferred Products   | Non Preferred Products   | Prior Authorization Criteria  |
|--|--|---|
| <b>Immunomodulators</b>  |  |   |
| <b>Targeted Immunomodulator</b>  |  |   |
| Actemra® PA<br>Avsola® PA<br>Cimzia® PA<br>Cosentyx® PA<br>Enbrel® PA<br>Humira® PA<br>Inflectra® PA<br>Kevzara® PA<br>Kineret® PA<br>Olumiant® PA<br>Orencia® PA<br>Otezla® PA<br>Renflexis® PA<br>Siliq® PA<br>Simponi® PA<br>Stelara® PA<br>Taltz® PA<br>Xeljanz® IR PA | Enspryng®<br>Entyvio®<br>Ilaris®<br>Ilumya®<br>Remicade®<br>Rinvoq®<br>Skyrizi®<br>Tremfya®<br>Xeljanz® ER |   |
| <b>Multiple Sclerosis Agents</b>   |  |   |
| <b>Injectable</b>  |  |   |
| Avonex® PA<br>Avonex® Admin Pack PA<br>Betaseron® PA<br>Copaxone® QL PA<br>Tysabri® PA   | Extavia®<br>glatiramer<br>Glatopa®<br>Kesimpta®<br>Lemtrada®<br>Ocrevus®<br>Plegridy®<br>Rebif® QL         | Trial of only one agent is required before moving to a non-preferred agent. |
| <b>Oral</b>  |  |   |
| Aubagio® PA<br>Gilenya® PA<br>Tecfidera® PA  | Bafiertam®<br>dimethyl fumarate<br>Mavenclad®<br>Mayzent®<br>Ponvory®<br>Vumerity®<br>Zeposia®             |   |
| <b>Specific Symptomatic Treatment</b>  |  |   |
| dalfampridine QL PA  | Ampyra® QL   |   |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## CARDIOVASCULAR AGENTS

| Preferred Products   | Non Preferred Products  | Prior Authorization Criteria           |
|--|---|--|
| <b>Antihypertensive Agents</b>   |   |  |
| <b>Angiotensin II Receptor Antagonists</b>   |   |  |
| losartan<br>losartan HCTZ<br>valsartan<br>valsartan HCTZ   | Atacand®<br>Avapro®<br>Benicar®<br>candesartan<br>Cozaar®<br>Diovan®<br>Diovan HCTZ®<br>Edarbi®<br>Edarbyclor®<br>eprosartan<br>Hyzaar®<br>irbesartan<br>Micardis®<br>telmisartan |  |
| <b>Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)</b>   |   |  |
| benazepril<br>benazepril HCTZ<br>captopril<br>captopril HCTZ<br>enalapril tab<br>enalapril HCTZ<br>Epaned® soln *PA<br>lisinopril<br>lisinopril HCTZ<br>ramipril   | Accuretic®<br>enalapril soln<br>fosinopril<br>Mavik®<br>moexipril<br>perindopril<br>Qbrelis® soln<br>quinapril<br>Quinaretic®<br>trandolapril                                     | *PA not required if age 10 and younger |
| <b>Beta-Blockers</b>   |   |  |
| acebutolol<br>atenolol<br>atenolol/chlorthalidone<br>bisoprolol<br>bisoprolol/HCTZ<br>Bystolic®<br>carvedilol IR<br>carvedilol ER<br>labetalol<br>metoprolol tartrate<br>metoprolol succinate<br>metoprolol/HCTZ<br>pindolol<br>propranolol<br>propranolol ER<br>propranolol/HCTZ<br>sotalol<br>sotalol AF | betaxolol<br>Kaspargo®<br>nadolol<br>nebivolol<br>Sotylize®<br>timolol  |  |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**CARDIOVASCULAR AGENTS**

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>Calcium-Channel Blockers</b>   |  |                              |
| amlodipine<br>amlodipine/benazepril<br>amlodipine/valsartan<br>Amlodipine/valsartan/ HCT<br>Cartia XT®<br>Diltia XT®<br>diltiazem ER<br>diltiazem IR<br>felodipine ER<br>nicardipine<br>nifedipine ER<br>Taztia XT®<br>verapamil IR<br>verapamil ER | Exforge®<br>Exforge HCT®<br>isradipine<br>Katerzia®<br>Lotrel®<br>nisoldipine ER<br>Norvasc®<br>Nymalize® solution |                              |
| <b>Vasodilators – Inhaled</b>   |  |                              |
| Ventavis® PA<br>Tyvaso® PA  |  |                              |
| <b>Vasodilators – Oral</b>  |  |                              |
| Orenitram® ER <sup>PA</sup><br>Revatio® <sup>PA</sup><br>tadalafil <sup>PA</sup><br>Tracleer® <sup>PA</sup>   | Adcirca®<br>Adempas®<br>Alyq®<br>ambrisentan<br>bosentan<br>Letairis®<br>Opsumit®<br>sildenafil<br>Uptravi®        |                              |
| <b>Antilipemics</b>   |  |                              |
| <b>Bile Acid Sequestrants</b>   |  |                              |
| colestipol<br>cholestyramine<br>Welchol®  | colesevelam<br>Questran®   |                              |
| <b>Cholesterol Absorption Inhibitors</b>  |  |                              |
| ezetimibe   | Zetia®   |                              |
| <b>Fibric Acid Derivatives</b>  |  |                              |
| fenofibrate<br>fenofibric<br>gemfibrozil  | Antara®<br>Fenoglide®<br>Fibricor®<br>Lipofen®<br>Tricor®<br>Triglide®<br>Trilipix®                                |                              |

## Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

### CARDIOVASCULAR AGENTS

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>HMG-CoA Reductase Inhibitors (Statins)</b>   |  |                              |
| atorvastatin<br>ezetimibe/simvastatin<br>lovastatin<br>pravastatin<br>rosuvastatin<br>simvastatin | Altoprev®<br>amlodipine/atorvastatin<br>Caduet®<br>Crestor® QL<br>Ezallor®<br>fluvastatin IR<br>fluvastatin XL<br>Lescol®<br>Lescol XL®<br>Lipitor®<br>Livalo®<br>Pravachol®<br>Zocor®<br>Zypitamag®<br>Vytorin® |                              |
| <b>Niacin Agents</b>  |  |                              |
| Niacin ER (all generics)<br>Niaspan®  | Niacor®  |                              |
| <b>Omega-3 Fatty Acids</b>  |  |                              |
| omega-3-acid<br>Vascepa®  | Lovaza®<br>icosapent   |                              |
| <b>PCSK9 Inhibitors</b>   |  |                              |
| Praluent® PA<br>Repatha® PA   |  |                              |
| <b>Miscellaneous Heart Failure Agents</b>   |  |                              |
| Corlanor® PA<br>Entresto® PA  | Verquvo®   |                              |

### DERMATOLOGICAL AGENTS

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>Antipsoriatic Agents</b>   |  |                              |
| Dovonex® cream<br>Sorilux® foam<br>Taclonex® susp<br>Vectical® oint | calcipotriene<br>calcipotriene/betamethasone oint<br>Duobrii® lotion<br>Enstilar®<br>Taclonex oint |                              |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## DERMATOLOGICAL AGENTS

| Preferred Products  | Non Preferred Products  | Prior Authorization Criteria           |
|---|---|--|
| <b>Topical Analgesics</b>   |   |  |
| capsaicin<br>Flector®<br>lidocaine<br>lidocaine HC<br>lidocaine viscous<br>lidocaine/prilocaine<br>Lidoderm® <sup>PA QL</sup><br>Pennsaid®<br>Voltaren® gel   | diclofenac gel/solution<br>Emla®<br>LenzaPro®<br>Licart®<br>lidocaine 5% patch <sup>PA QL</sup><br>ZTLido®  |  |
| <b>Topical Anti-infectives</b>  |   |  |
| <b>Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products</b>  |   |  |
| Acanya® <sup>PA*</sup><br>Azelex® 20% cream <sup>PA*</sup><br>benzoyl peroxide (2.5%, 5%, and 10% only) <sup>PA*</sup><br>clindamycin <sup>PA*</sup><br>erythromycin/benzoyl peroxide sodium <sup>PA*</sup> | Aczone® gel<br>Amzeeq® foam<br>benzoyl per aerosol<br>clindamycin aerosol<br>clindamycin/benzoyl peroxide gel<br>dapsone gel<br>Duac CS®<br>erythromycin<br>Onexton® gel<br>sodium sulfacetamide/sulfur<br>sulfacetamide<br>Winlevi | *PA not required if under 21 years old |
| <b>Impetigo Agents: Topical</b>   |   |  |
| mupirocin oint  | Altabax®<br>Centany®<br>mupirocin cream   |  |
| <b>Topical Antivirals</b>   |   |  |
| Abreva®<br>Denavir®<br>Xerese® cream<br>Zovirax® cream<br>Zovirax® oint   | acyclovir cream<br>acyclovir oint   |  |
| <b>Topical Scabicides</b>   |   |  |
| lindane<br>Natroba®<br>Nix®<br>permethrin<br>Rid®<br>Ulesfia®   | Eurax®<br>ivermectin<br>malathion<br>Ovide®<br>Sklice®<br>spinosad<br>Vanallice® gel  |  |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**DERMATOLOGICAL AGENTS**

| Preferred Products   | Non Preferred Products   | Prior Authorization Criteria           |
|--|--|--|
| <b>Topical Anti-inflammatory Agents</b>  |  |  |
| <b>Immunomodulators: Topical</b>   |  |  |
| Elidel <sup>®</sup> QL PA<br>Eucrisa <sup>®</sup> PA<br>Protopic <sup>®</sup> QL PA  | pimecrolimus<br>tacrolimus   |  |
| <b>Topical Antineoplastics</b>   |  |  |
| <b>Topical Retinoids</b>   |  |  |
| Differin <sup>®</sup> PA*<br>Epiduo <sup>®</sup> PA*<br>Retin-A <sup>PA*</sup><br>Tazorac <sup>®</sup> PA*<br>Ziana <sup>®</sup> PA* | Arazlo <sup>®</sup><br>adapalene gel and cream<br>adapalene/benzoyl peroxide<br>Atralin <sup>®</sup><br>Avita <sup>®</sup><br>Retin-A Micro <sup>®</sup> (pump and tube)<br>tazarotene<br>tretinoin<br>Veltin <sup>®</sup> | *PA not required if under 21 years old |

**ELECTROLYTIC AND RENAL AGENTS**

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>Phosphate Binding Agents</b>   |  |                              |
| calcium acetate cap<br>calcium acetate tab<br>Phoslyra <sup>®</sup><br>Renagel <sup>®</sup><br>Renvela <sup>®</sup> | Auryxia <sup>®</sup><br>Fosrenol <sup>®</sup><br>lanthanum carbonate<br>PhosLo <sup>®</sup> gel cap<br>sevelamer carbonate<br>sevelamer HCL<br>Velphoro <sup>®</sup> |                              |
| <b>Potassium Removing Agents</b>  |  |                              |
| Lokelma <sup>®</sup><br>sodium polystyrene sulfonate<br>SPS <sup>®</sup>  | Veltassa <sup>®</sup>  |                              |



Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**GASTROINTESTINAL AGENTS**

| Preferred Products  | Non Preferred Products  | Prior Authorization Criteria      |
|---|---|-----------------------------------|
| <b>Antiemetics</b>  |   |                                   |
| <b>Pregnancy-induced Nausea and Vomiting Treatment</b>                            |   |                                   |
| Bonjesta®<br>OTC doxylamine 25 mg/pyridoxine 10 mg                                | Diclegis®<br>doxylamine-pyridoxine tab 10-10  |                                   |
| <b>Serotonin-receptor antagonists/Combo</b>                                       |   |                                   |
| granisetron <sup>QL PA</sup><br>ondansetron <sup>QL PA</sup>                      | Akynzeo®<br>Anzemet® <sup>QL</sup><br>Barhemsys®<br>Sancuso®<br>Zofran® <sup>QL</sup><br>Zuplenz® <sup>QL</sup>                           |                                   |
| <b>Antiulcer Agents</b>   |   |                                   |
| <b>H2 Blockers</b>  |   |                                   |
| Famotidine tab and susp<br>ranitidine tab<br>ranitidine syrup <sup>PA</sup>       |   | * PA not required for < 12 years. |
| <b>Proton Pump Inhibitors (PPIs)</b>  |   |                                   |
| Dexilant®<br>Nexium® powder for susp <sup>PA*</sup><br>omeprazole<br>pantoprazole | Aciphex®<br>esomeprazole<br>lansoprazole<br>Nexium® cap<br>Prevacid®<br>Prilosec®<br>Prilosec® OTC tab<br>Protonix®<br>rabeprazole sodium | * PA not required for < 12 years. |
| <b>Functional Gastrointestinal Disorder Drugs</b>                                 |   |                                   |
| Amitiza® <sup>PA</sup><br>Linzess® <sup>PA</sup>                                  | Lubiprostone<br>Motegrity®<br>Movantik®<br>Relistor®<br>Symproic®<br>Trulance®<br>Zelnorm®  |                                   |

## Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

### GASTROINTESTINAL AGENTS

| Preferred Products   | Non Preferred Products  | Prior Authorization Criteria |
|--|---|------------------------------|
| <b>Gastrointestinal Anti-inflammatory Agents</b>   |   |                              |
| Apriso®<br>Canasa® supp<br>Colazal®<br>Delzicol®<br>Pentasa®<br>sulfasalazine DR<br>sulfasalazine IR | balsalazide<br>Lialda®<br>mesalamine (generic for Apriso)<br>mesalamine (generic for Asacol HD)<br>mesalamine (generic for Delzicol)<br>mesalamine (generic Lialda)<br>mesalamine enema susp<br>mesalamine supp |                              |
| <b>Gastrointestinal Enzymes</b>  |   |                              |
| Creon®<br>Pancreaze®<br>Zenpep®  | Pertzye®<br>Viokace®  |                              |

### GENITOURINARY AGENTS

| Preferred Products   | Non Preferred Products   | Prior Authorization Criteria |
|--|--|------------------------------|
| <b>Benign Prostatic Hyperplasia (BPH) Agents</b>   |  |                              |
| <b>5-Alpha Reductase Inhibitors</b>  |  |                              |
| dutasteride<br>finasteride   | Avodart®<br>dutasteride/tamsulosin<br>Jalyn®<br>Proscar®   |                              |
| <b>Alpha-Blockers</b>  |  |                              |
| alfuzosin<br>doxazosin<br>tamsulosin<br>terazosin  | Cardura®<br>Flomax®<br>Minipress®<br>prazosin<br>Rapaflo®<br>silodosin<br>Uroxatral®   |                              |
| <b>Bladder Antispasmodics</b>  |  |                              |
| bethanechol<br>Detrol®<br>Detrol LA®<br>oxybutynin IR and ER tab/syrup<br>solifenacin<br>Toviaz® | darifenacin ER<br>Ditropan XL®<br>flavoxate<br>Gelnique® gel<br>Gemtesa<br>Myrbetriq®<br>Oxytrol®<br>Sanctura®<br>tolterodine<br>trospium<br>Vesicare®<br>Vesicare® LS |                              |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## HEMATOLOGICAL AGENTS

| Preferred Products   | Non Preferred Products  | Prior Authorization Criteria                                      |
|--|---|---|
| <b>Anticoagulants</b>  |   |   |
| <b>Oral</b>  |   |   |
| Coumadin®<br>Eliquis® PA*<br>Jantoven®<br>Pradaxa® QL PA*<br>Warfarin<br>Xarelto® PA*              | Savaysa®  | * No PA required if approved diagnosis code transmitted on claim. |
| <b>Injectable</b>  |   |   |
| enoxaparin<br>fondaparinux<br>Fragmin®   | Arixtra®<br>Lovenox®  |   |
| <b>Erythropoiesis-Stimulating Agents</b>   |   |   |
| Aranesp® PA QL<br>Retacrit® PA   | Epogen® PA QL<br>Mircera® PA QL<br>Procrit® PA QL   |   |
| <b>Platelet Inhibitors</b>   |   |   |
| Aggrenox®<br>aspirin<br>Brilinta® QL PA<br>Cilostazol®<br>Clopidogrel<br>Dipyridamole<br>Prasugrel | anagrelide<br>aspirin/dipyridamole<br>Durlaza®<br>Effient® QL<br>Plavix®<br>Yosprala®<br>Zontivity® |   |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## HORMONES AND HORMONE MODIFIERS

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria                                    |
|---|--|---|
| <b>Androgens</b>  |  |   |
| Androderm <sup>®</sup> PA   | AndroGel <sup>®</sup><br>Fortesta <sup>®</sup><br>Natesto <sup>®</sup><br>Testim <sup>®</sup><br>testosterone gel<br>testosterone solution<br>Vogelxo <sup>®</sup> |   |
| <b>Antidiabetic Agents</b>  |  |   |
| <b>Alpha-Glucosidase Inhibitors/Amylin analogs/Misc.</b>  |  |   |
| acarbose<br>Glyset <sup>®</sup><br>Symlin <sup>®</sup> PA *   | Cycloset <sup>®</sup><br>Precose <sup>®</sup>  | * No PA required if Dx of Type 2 Diabetes transmitted on claim. |
| <b>Biguanides</b>   |  |   |
| metformin (generic for Glucophage <sup>®</sup> )<br>metformin ER (generic for Glucophage XR <sup>®</sup> )<br>metformin ER (generic for Glumetza <sup>®</sup> )<br>Riomet <sup>®</sup>                    | Glumetza <sup>®</sup><br>metformin ER (generic for Fortamet <sup>®</sup> )   |   |
| <b>Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin</b>  |  |   |
| Janumet <sup>®</sup><br>Janumet XR <sup>®</sup><br>Januvia <sup>®</sup><br>Jentadueto <sup>®</sup><br>Kombiglyze XR <sup>®</sup><br>Onglyza <sup>®</sup><br>Tadjenta <sup>®</sup>                         | alogliptin<br>alogliptin/metformin<br>alogliptin/pioglitazone<br>Kazano <sup>®</sup><br>Nesina <sup>®</sup><br>Oseni <sup>®</sup>                                  |   |
| <b>Incretin Mimetics and Combinations</b>   |  |   |
| Byetta <sup>®</sup> PA, QL *<br>Ozempic <sup>®</sup> PA *<br>Rybelsus <sup>®</sup> PA, QL *<br>Trulicity <sup>®</sup> PA, QL *<br>Victoza <sup>®</sup> PA, QL *   | Adlyxin <sup>®</sup> QL<br>Bydureon BCise <sup>®</sup> QL<br>Soliqua <sup>®</sup> QL<br>Xultophy <sup>®</sup> QL   | * No PA required if Dx of Type 2 Diabetes transmitted on claim. |
| <b>Meglitinides</b>   |  |   |
| repaglinide   | nateglinide  |   |
| <b>Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations</b>  |  |   |
| Farxiga <sup>®</sup><br>Glyxambi <sup>®</sup><br>Invokamet <sup>®</sup><br>Invokana <sup>®</sup><br>Jardiance <sup>®</sup><br>Synjardy <sup>®</sup><br>Synjardy XR <sup>®</sup><br>Xigduo XR <sup>®</sup> | Invokamet XR <sup>®</sup><br>Qtern <sup>®</sup><br>Segluromet <sup>®</sup><br>Steglatro <sup>®</sup><br>Steglujan <sup>®</sup><br>Trijardy XR <sup>®</sup>         |   |

# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## HORMONES AND HORMONE MODIFIERS

| Preferred Products   | Non Preferred Products   | Prior Authorization Criteria |
|--|--|------------------------------|
| <b>Sulfonylureas</b>   |  |                              |
| glimepiride (generic for Amaryl®)<br>glipizide (generic for Glucotrol®)<br>glipizide ER (generic for Glucotrol XL®)<br>glyburide (generic for DiaBeta®, Micronase®)<br>glyburide micronized (generic for Glynase®) | Amaryl®<br>Glynase®<br>Glucotrol XL®<br>glyburide/metformin (generic for Glucovance®)<br>glipizide/metformin (generic for Metaglip®) |                              |
| <b>Thiazolidinediones and Combinations</b>   |  |                              |
| pioglitazone   | Actos®<br>Actoplus Met®<br>Duetact®<br>pioglitazone/metformin<br>pioglitazone/glimepiride  |                              |
| <b>Anti-Hypoglycemic Agents</b>  |  |                              |
| Baqsimi®<br>GlucaGen HypoKit®<br>Zegalogue®  | glucagon emergency kit<br>Gvoke®   |                              |
| <b>Insulins</b>  |  |                              |
| <b>Rapid Acting Insulins</b>   |  |                              |
| Apidra®<br>Apidra Solostar®<br>Humalog®<br>Humalog KwikPen® U-100<br>Humalog Junior KwikPen®<br>insulin aspart (generic for Novolog®)<br>insulin lispro (generic for Humalog®)<br>Novolog®                         | Admelog®<br>Admelog Solostar®<br>Afrezza®<br>Fiasp®<br>Fiasp FlexTouch®<br>Humalog KwikPen® U-200<br>Lyumjev®<br>Lyumjev KwikPen®    |                              |
| <b>Short-Intermediate Acting Insulins</b>  |  |                              |
| Humulin R® U-500<br>Novolin N®<br>Novolin R®   | Humulin N®<br>Humulin N KwikPen®<br>Humulin R® U-100   |                              |
| <b>Long-Acting Insulins</b>  |  |                              |
| Lantus®<br>Lantus SoloStar®<br>Levemir®<br>Toujeo Max SoloStar®<br>Toujeo SoloStar®<br>Tresiba®<br>Tresiba FlexTouch®  | Basaglar KwikPen®<br>Semglee®  |                              |
| <b>Pre-Mixed Insulin Combinations</b>  |  |                              |
| Humulin 70/30®   | Novolin 70/30®   |                              |

## Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

### HORMONES AND HORMONE MODIFIERS

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>Pituitary Hormones</b>                                 |  |                              |
| <b>Growth Hormone Modifiers</b>                           |  |                              |
| Genotropin <sup>®</sup> PA<br>Norditropin <sup>®</sup> PA | Humatrope <sup>®</sup><br>Nutropin AQ <sup>®</sup> NuSpin <sup>®</sup><br>Nutropin <sup>®</sup><br>Omnitrope <sup>®</sup><br>Saizen <sup>®</sup><br>Serostim <sup>®</sup><br>Somavert <sup>®</sup><br>Tev-Tropin <sup>®</sup><br>Zorbtive <sup>®</sup> |                              |
| <b>Progestins for Cachexia</b>                            |  |                              |
| megestrol acetate susp (generic for Megace <sup>®</sup> ) | Megace ES <sup>®</sup>   |                              |

### MONOCLONAL ANTIBODIES FOR THE TREATMENT OF RESPIRATORY CONDITIONS

| Preferred Products  | Non Preferred Products  | Prior Authorization Criteria |
|---|-------------------------|------------------------------|
| Dupixent <sup>®</sup> PA<br>Fasenra <sup>®</sup> PA<br>Nucala <sup>®</sup> PA<br>Xolair <sup>®</sup> PA | Cinqair <sup>®</sup> PA |                              |

### MUSCULOSKELETAL AGENTS

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>Antigout Agents</b>  |  |                              |
| allopurinol<br>Colcrys <sup>®</sup> QL<br>febuxostat<br>probenecid<br>probenecid/colchicine | colchicine cap, tab <sup>QL</sup><br>Mitigare <sup>®</sup> QL<br>Uloric <sup>®</sup><br>Zyloprim <sup>®</sup>  |                              |
| <b>Bone Resorption Inhibitors</b>   |  |                              |
| <b>Bisphosphonates</b>  |  |                              |
| alendronate tab   | Actonel <sup>®</sup><br>alendronate soln<br>Atelvia <sup>®</sup><br>Binosto <sup>®</sup><br>Boniva <sup>®</sup><br>etidronate (generic for Didronel <sup>®</sup> )<br>Fosamax Plus D <sup>®</sup><br>ibandronate |                              |
| <b>Nasal Calcitonins</b>  |  |                              |
| calcitonin-salmon nasal spray   | Miacalcin <sup>®</sup>   |                              |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**MUSCULOSKELETAL AGENTS**

| Preferred Products   | Non Preferred Products | Prior Authorization Criteria |
|--|------------------------|------------------------------|
| <b>Restless Leg Syndrome Agents</b>  |                        |                              |
| Mirapex® ER<br>pramipexole IR<br>ropinirole IR<br>ropinirole ER  |                        |                              |
| <b>Skeletal Muscle Relaxants</b>   |                        |                              |
| baclofen<br>chlorzoxazone<br>cyclobenzaprine IR<br>cyclobenzaprine ER<br>dantrolene<br>methocarbamol<br>orphenadrine<br>tizanidine |                        |                              |

**NEUROLOGICAL AGENTS**

| Preferred Products                  | Non Preferred Products   | Prior Authorization Criteria |
|-------------------------------------|--|------------------------------|
| <b>Alzheimer's Agents</b>           |  |                              |
| <b>Cholinesterase Inhibitors</b>    |  |                              |
| donepezil tab, ODT<br>Exelon® patch | Aricept®<br>galantamine<br>galantamine ER<br>Razadyne® ER<br>rivastigmine                        |                              |
| <b>NMDA Receptor Antagonist</b>     |  |                              |
| memantine IR tab                    | memantine soln<br>memantine ER (generic for Namenda XR®)<br>Namenda®<br>Namenda XR®<br>Namzaric® |                              |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**NEUROLOGICAL AGENTS**

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria                |
|---|--|---|
| <b>Anticonvulsants</b>  |  |   |
| carbamazepine<br>carbamazepine ER cap (generic for Carbatrol®)<br>carbamazepine ER tab (generic for Tegretol XR®)<br>Carbatrol®<br>Celontin®<br>Depakene®<br>Depakote®<br>Depakote ER®<br>Depakote Sprinkle®<br>divalproex sodium<br>divalproex sodium ER<br>Epidiolex® PA<br>Epitol®<br>ethosuximide<br>felbamate<br>Felbatol®<br>Fintepla® PA<br>Fycompa®<br>gabapentin<br>Gabitril®<br>lacosamide<br>Lamictal®<br>Lamictal ODT®<br>lamotrigine<br>lamotrigine ER<br>levetiracetam<br>levetiracetam ER<br>Lyrica®<br>Neurontin®<br>oxcarbazepine<br>Qudexy XR®<br>Tegretol®<br>Tegretol XR®<br>Topamax®<br>topiramate IR<br>Trileptal®<br>valproic acid<br>Zarontin®<br>Zonegran®<br>zonisamide | Aptiom®<br>Banzel®<br>Briviact®<br>Diacomit®<br>Eprontia®<br>Keppra®<br>Keppra XR®<br>Lamictal XR®<br>Oxtellar XR®<br>Sabril®<br>Spritam®<br>topiramate ER<br>Trokendi XR®<br>Vigabatrin<br>Vimpat®<br>Xcopri® | PA required for members under 18 years old. |
| <b>Barbiturates</b>   |  |   |
| Mysoline®<br>phenobarbital<br>primidone   |  | PA required for members under 18 years old. |



# Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

## NEUROLOGICAL AGENTS

| Preferred Products   | Non Preferred Products  | Prior Authorization Criteria                |
|--|---|---|
| <b>Benzodiazepines</b>   |   |   |
| clobazam<br>clonazepam<br>clorazepate<br>Diastat®<br>diazepam (generic for Valium®)<br>Nayzilam® spray <sup>PA</sup><br>Tranxene T-Tab®<br>Valium®<br>Valtoco® spray <sup>PA</sup>   | diazepam rectal (generic for Diastat®)<br>Klonopin®<br>Onfi®<br>Sympazan®   | PA required for members under 18 years old. |
| <b>Hydantoins</b>  |   |   |
| Cerebyx®<br>Dilantin®<br>fosphenytoin<br>Phenytek®<br>phenytoin products   |   |   |
| <b>Anti-Migraine Agents</b>  |   |   |
| <b>Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists</b>   |   |   |
| Aimovig® <sup>PA</sup><br>Ajovy® <sup>PA</sup><br>Emgality® <sup>PA</sup><br>Nurtec® ODT <sup>PA, QL</sup><br>Qulipta® <sup>PA, QL</sup>   | Ubrelvy® <sup>QL</sup><br>Vyepti®   |   |
| <b>Serotonin-Receptor Agonists (Triptans)</b>  |   |   |
| Frova® <sup>QL</sup><br>Relpax® <sup>QL</sup><br>rizatriptan ODT (generic for Maxalt MLT®)<br><sup>QL</sup><br>sumatriptan tab <sup>QL</sup><br>zolmitriptan nasal spray <sup>QL</sup><br>zolmitriptan ODT (generic for Zomig ZMT®)<br><sup>QL</sup> | almotriptan <sup>QL</sup><br>Amerge® <sup>QL</sup><br>eletriptan <sup>QL</sup><br>frovatriptan <sup>QL</sup><br>Imitrex® <sup>QL</sup><br>Maxalt® <sup>QL</sup><br>Maxalt MLT® <sup>QL</sup><br>naratriptan <sup>QL</sup><br>Onzetra®<br>Reyvow®<br>rizatriptan tab (generic for Maxalt®)<br><sup>QL</sup><br>sumatriptan inj <sup>QL</sup><br>sumatriptan nasal spray <sup>QL</sup><br>sumatriptan/naproxen <sup>QL</sup><br>Tosymra®<br>Treximet®<br>Zembrace SymTouch®<br>zolmitriptan tab <sup>QL</sup><br>Zomig® nasal spray <sup>QL</sup><br>Zomig® tab <sup>QL</sup><br>Zomig ZMT® |   |

## Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

### NEUROLOGICAL AGENTS

| Preferred Products   | Non Preferred Products                                  | Prior Authorization Criteria  |
|--|---|---|
| <b>Antiparkinsonian Agents</b>   |   |   |
| <b>Dopamine Precursors</b>   |   |   |
| carbidopa/levodopa<br>carbidopa/levodopa ER<br>carbidopa/levodopa ODT<br>carbidopa/levodopa/entacapone | Duopa®<br>Inbrija®<br>Lodosyn®<br>Rytary®<br>Stalevo®   | Trial of only one preferred agent is required before moving to a non-preferred agent. |
| <b>Non-Ergot Dopamine Agonists</b>   |   |   |
| Mirapex® ER<br>pramipexole IR<br>ropinirole IR<br>ropinirole ER  | Apokyn®<br>Mirapex®<br>Neupro®<br>Requip®<br>Requip XL® |   |
| <b>Movement Disorders</b>  |   |   |
| Austedo® PA<br>Ingrezza® PA<br>tetrabenazine   | Xenazine®   |   |

### OPHTHALMIC AGENTS

| Preferred Products  | Non Preferred Products  | Prior Authorization Criteria |
|---|---|------------------------------|
| <b>Antiglaucoma Agents</b>  |   |                              |
| Alphagan P®<br>Azopt®<br>betaxolol<br>Betoptic S®<br>carteolol<br>Combigan®<br>dorzolamide<br>dorzolamide/timolol<br>latanoprost<br>levobunolol<br>Lumigan®<br>Rhopressa®<br>Rocklatan®<br>Simbrinza®<br>timolol drops, gel soln (generic for Timoptic®, Timoptic-XE®)<br>Travatan Z® | Betagan®<br>Betoptic®<br>bimatoprost<br>brimonidine<br>brimonidine/timolol<br>brinzolamide<br>Cosopt®<br>Cosopt PF®<br>dorzolamide/timolol PF<br>Ocupress®<br>Timoptic®<br>Timoptic-XE®<br>travoprost<br>Trusopt®<br>Vyzulta®<br>Xalatan®<br>Xelpros®<br>Zioptan® |                              |
| <b>Ophthalmic Antihistamines</b>  |   |                              |
| azelastine<br>Bepreve®<br>ketotifen (generic for Alaway®, Zaditor®)<br>Lastacaft®   | Alaway® OTC<br>Alocril®<br>Alomide®<br>bepotastine  |                              |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**OPHTHALMIC AGENTS**

| Preferred Products   | Non Preferred Products   | Prior Authorization Criteria |
|--|--|------------------------------|
| olopatadine (generic for Pataday®)<br>Zaditor® OTC   | Elestat®<br>Optivar®<br>Pataday®<br>Zerviate®  |                              |
| <b>Ophthalmic Anti-infectives</b>  |  |                              |
| <b>Ophthalmic Macrolides</b>   |  |                              |
| erythromycin oint  |  |                              |
| <b>Ophthalmic Quinolones</b>   |  |                              |
| Besivance®<br>ciprofloxacin<br>Vigamox®<br>Zymaxid®  | Ciloxan®<br>gatifloxacin<br>levofloxacin<br>Moxeza®<br>moxifloxacin<br>ofloxacin   |                              |
| <b>Ophthalmic Anti-infective/Anti-inflammatory Combinations</b>  |  |                              |
| neomycin/polymyxin/dexamethasone oint, susp<br>Pred-G®<br>sulfacetamide/prednisolone soln<br>TobraDex®<br>Zylet® | Blephamide®<br>Maxitrol®<br>neomycin/bacitracin/polymyxin/hydrocortisone oint<br>neomycin/polymyxin/hydrocortisone susp<br>tobramycin/dexamethasone susp<br>TobraDex ST® |                              |
| <b>Ophthalmic Anti-inflammatory Agents</b>   |  |                              |
| <b>Ophthalmic Corticosteroids</b>  |  |                              |
| Alrex®<br>Durezol®<br>Flarex®<br>FML®<br>FML Forte®<br>Maxidex®<br>Pred Forte®                                   | dexamethasone<br>fluorometholone<br>Inveltys®<br>Lotemax®<br>loteprednol<br>Omnipred®<br>Pred Mild®<br>prednisolone  |                              |
| <b>Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</b>  |  |                              |
| diclofenac soln<br>flurbiprofen soln<br>Ilevro®<br>ketorolac soln<br>Nevanac®                                    | Acular®<br>Acular LS®<br>Acuvail®<br>bromfenac<br>Prolensa®  |                              |
| <b>Ophthalmics for Dry Eye Disease</b>   |  |                              |
| artificial tears<br>Restasis®<br>Xiidra®   | Cequa®<br>Eysuvis®<br>Restasis Multidose®<br>Tyrvaya®  |                              |

## Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

### OTIC AGENTS

| Preferred Products                  | Non Preferred Products                                      | Prior Authorization Criteria |
|-------------------------------------|---|------------------------------|
| <b>Otic Anti-infectives</b>         |   |                              |
| <b>Otic Quinolones</b>              |   |                              |
| Ciprodex®<br>Cipro HC®<br>ofloxacin | Cetraxal®<br>ciprofloxacin 0.2% soln<br>Otiprio®<br>Otovel® |                              |

### PSYCHOTROPIC AGENTS

| Preferred Products   | Non-Preferred Products  | Prior Authorization Criteria  |
|--|---|-------------------------------|
| <b>ADHD Agents</b>   |   |                               |
| Adderall XR® PA, QL<br>amphetamine salts combo IR (generic for Adderall®) PA<br>atomoxetine PA, QL<br>Concerta® PA, QL<br>Daytrana® PA, QL<br>dexmethylphenidate PA<br>dextroamphetamine (generic for Dexedrine®, Dextrostat®) PA<br>dextroamphetamine SR (generic for Dexedrine Spansule®) PA<br>Focalin XR® PA, QL<br>guanfacine ER PA<br>Jornay PM® PA<br>Metadate CD® PA<br>Methylin® PA<br>methylphenidate (generic for Ritalin®, Methylin®) PA<br>methylphenidate CD (generic for Metadate CD®) PA, QL<br>methylphenidate ER (generic for Aptensio XR®) PA, QL<br>methylphenidate LA (generic for Ritalin LA®) PA, QL<br>methylphenidate solution PA<br>Qelbree® PA, QL<br>Ritalin LA® PA, QL<br>Stratterra® PA, QL<br>Vyvanse® PA, QL | Adderall®<br>Adhansia XR®<br>Adzenys XR ODT®<br>amphetamine ER susp (generic for Adzenys XR ODT®)<br>amphetamine salts combo ER (generic for Adderall XR®) QL<br>Aptensio XR® QL<br>Azstarys®<br>clonidine ER QL<br>Cotempla XR-ODT®<br>Desoxyn®<br>Dexedrine® QL<br>dextroamphetamine soln (generic for ProCentra®)<br>Dyanavel XR® QL<br>Evekeo®<br>Evekeo ODT®<br>Focalin®<br>Intuniv® QL<br>Metadate ER® QL<br>methylphenidate chew<br>methylphenidate ER (generic for Relexxii®) QL<br>Mydayis®<br>ProCentra®<br>QuilliChew ER® QL<br>Quillivant XR® QL<br>Relexxii®<br>Ritalin®<br>Zenzedi® | PA required for entire class. |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**PSYCHOTROPIC AGENTS**

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria   |
|---|--|--|
| <b>Antidepressants</b>  |  |  |
| <b>Other</b>  |  |  |
| bupropion IR<br>bupropion SR<br>bupropion XL<br>duloxetine<br>mirtazapine<br>mirtazapine ODT<br>Pristiq®<br>trazodone<br>venlafaxine<br>venlafaxine ER  | Aplenzin®<br>Cymbalta®<br>desvenlafaxine ER<br>desvenlafaxine fumarate ER<br>desvenlafaxine succinate ER<br>Effexor XR®<br>Fetzima®<br>Forfivo XL®<br>Trintellix®<br>Viibryd®<br>Wellbutrin SR®<br>Wellbutrin XL®                    | PA required for members under 18 years old.  |
| <b>Selective Serotonin Reuptake Inhibitors (SSRIs)</b>  |  |  |
| citalopram<br>escitalopram<br>fluoxetine paroxetine IR<br>Pexeva®<br>sertraline   | Celexa®<br>fluvoxamine<br>Lexapro®<br>Luvox®<br>paroxetine ER<br>Paxil®<br>Prozac®<br>Zoloft®  | PA required for members under 18 years old.  |
| <b>Antipsychotics</b>   |  |  |
| <b>Atypical Antipsychotics – Oral/Topical</b>   |  |  |
| aripiprazole<br>clozapine<br>clozapine ODT<br>Fanapt®<br>Geodon®<br>Invega®<br>Latuda®<br>Nuplazid® *<br>olanzapine<br>olanzapine ODT<br>quetiapine IR<br>quetiapine ER<br>Rexulti®<br>risperidone<br>risperidone ODT<br>Saphris®<br>Vraylar® | Abilify®<br>Abilify MyCite®<br>asenapine<br>Caplyta®<br>Clozaril®<br>Fazaclo®<br>Lybalvi®<br>paliperidone ER<br>Risperdal®<br>Risperdal M-Tab®<br>Secuado®<br>Seroquel®<br>Seroquel XR®<br>ziprasidone<br>Zyprexa®<br>Zyprexa Zydis® | PA required for members under 18 years old.<br>* No PA required if Parkinson’s related psychosis ICD code on claim |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**PSYCHOTROPIC AGENTS**

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria  |
|---|--|---|
| <b>Atypical Antipsychotics – Long Acting Injectable</b>   |  |   |
| Abilify Maintena®<br>Aristada®<br>Aristada Initio®<br>Invega Hafyera®<br>Invega Sustenna®<br>Invega Trinza® PA<br>Perseris®<br>Risperdal Consta®<br>Zyprexa Relprevv® |  | PA required for members under 18 years old.   |
| <b>Anxiolytics, Sedatives, and Hypnotics</b>  |  |   |
| estazolam QL<br>flurazepam QL<br>Rozerem® QL<br>temazepam QL<br>triazolam QL<br>zaleplon QL<br>zolpidem IR QL<br>zolpidem SL QL                                       | Ambien® QL<br>Ambien CR® QL<br>Belsomra® QL<br>Doral® QL<br>Edluar® QL<br>eszopiclone<br>Hetlioz®<br>Hetlioz LQ®<br>Lunesta®<br>Silenor® QL<br>Sonata®<br>zolpidem CR QL<br>Zolpimist® | No PA required if approved diagnosis code transmitted on claim (all agents in this class).<br>PA required for members under 18 years old. |
| <b>Psychostimulants</b>   |  |   |
| <b>Narcolepsy Agents</b>  |  |   |
| Nuvigil® PA, QL *<br>Provigil® PA, QL *<br>Wakix® PA  | armodafinil QL *<br>modafinil QL *<br>Sunosi<br>Xyrem® QL<br>Xywav®  | * No PA required for ICD-10 code G47.4  |

**RESPIRATORY AGENTS**

| Preferred Products                                | Non Preferred Products                 | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>Nasal Antihistamines</b>                       |  |                              |
| azelastine<br>Dymista®<br>olopatadine             | Patanase®                              |                              |
| <b>Respiratory Anti-inflammatory Agents</b>       |  |                              |
| <b>Leukotriene Receptor Antagonists</b>           |  |                              |
| montelukast<br>zafirlukast<br>Zyflo®<br>Zyflo CR® | Accolate®<br>Singulair®<br>zileuton ER |                              |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**RESPIRATORY AGENTS**

| Preferred Products  | Non Preferred Products  | Prior Authorization Criteria |
|---|---|------------------------------|
| <b>Nasal Corticosteroids</b>  |   |                              |
| fluticasone (generic for Flonase®)<br>triamcinolone acetonide   | Beconase AQ®<br>Flonase®<br>flunisolide<br>Nasonex®<br>Omnaris®<br>Qnasl®<br>Xhance®<br>Zetonna®  |                              |
| <b>Phosphodiesterase Type 4 Inhibitors</b>  |   |                              |
| Daliresp® PA, QL  |   |                              |
| <b>Long-Acting Maintenance Therapy</b>  |   |                              |
| <b>Inhaled Glucocorticoids</b>  |   |                              |
| budesonide nebs (generic for Pulmicort®)<br>Flovent Diskus®<br>Flovent HFA® QL<br>Pulmicort Flexhaler®        | Alvesco®<br>ArmonAir Digihaler®<br>Arnuity Ellipta®<br>Asmanex HFA®<br>QVAR RediHaler®  |                              |
| <b>Glucocorticoids/Long-Acting Beta-2 Adrenergic (LABA) Combination Products</b>                              |   |                              |
| Advair® Diskus<br>Advair HFA®<br>Breo Ellipta®<br>Dulera®<br>Symbicort®                                       | AirDuo Digihaler®<br>AirDuo RespiClick®<br>budesonide/formoterol (generic for Symbicort®)<br>fluticasone propionate/salmeterol pow (generic for AirDuo®, Advair Diskus®)<br>Wixela Inhub® |                              |
| <b>Long-Acting Beta Adrenergics (LABA)</b>  |   |                              |
| Serevent Diskus® QL<br>Striverdi Respimat®  | Brovana®<br>Perforomist®  |                              |
| <b>Anticholinergics and Combination Products</b>  |   |                              |
| Anoro Ellipta®<br>Incruse Ellipta®<br>Spiriva®<br>Spiriva Respimat®<br>Stiolto Respimat®<br>Tudorza Pressair® | Bevespi Aerosphere®<br>Breztri Aerosphere®<br>Duaklir Pressair®<br>Lonhala Magnair®<br>Trelegy Ellipta®<br>Yupelri®   |                              |

Nevada Medicaid and Nevada Check Up Preferred Drug List (PDL)

Effective July 20, 2022

**RESPIRATORY AGENTS**

| Preferred Products  | Non Preferred Products   | Prior Authorization Criteria |
|---|--|------------------------------|
| <b>Short-Acting/Rescue Therapy</b>  |  |                              |
| <b>Short-Acting Beta Adrenergic (SABA)</b>  |  |                              |
| albuterol sulfate (generic for Proventil <sup>®</sup> , Ventolin <sup>®</sup> ) <sup>QL</sup><br>albuterol soln (generic for AccuNeb <sup>®</sup> ) <sup>QL</sup><br>Proair HFA <sup>® QL</sup><br>Ventolin HFA <sup>® QL</sup><br>Xopenex <sup>® PA, QL</sup><br>Xopenex HFA <sup>® PA, QL</sup> | albuterol HFA (generic for ProAir HFA <sup>®</sup> , Ventolin HFA <sup>®</sup> ) <sup>QL</sup><br>levalbuterol <sup>QL</sup><br>levalbuterol HFA <sup>QL</sup><br>ProAir Digihaler <sup>® QL</sup><br>ProAir RespiClick <sup>® QL</sup><br>Proventil HFA <sup>® QL</sup> |                              |
| <b>Ipratropium and Combinations</b>   |  |                              |
| Atrovent HFA <sup>®</sup><br>Combivent Respimat <sup>®</sup><br>ipratropium nebs<br>ipratropium/albuterol nebs <sup>QL</sup>  |  |                              |

**TOXICOLOGY AGENTS**

| Preferred Products  | Non Preferred Products  | Prior Authorization Criteria |
|---|---|------------------------------|
| <b>Antidotes</b>  |   |                              |
| <b>Opiate Antagonists</b>   |   |                              |
| Kloxxado <sup>®</sup><br>naloxone<br>Narcan <sup>®</sup>  |   |                              |
| <b>Substance Abuse Agents</b>   |   |                              |
| buprenorphine SL tab <sup>QL</sup><br>buprenorphine/naloxone SL tab <sup>QL</sup><br>Sublocade <sup>®</sup><br>Suboxone <sup>® QL</sup><br>Vivitrol <sup>® PA</sup> | Bunavail <sup>®</sup><br>buprenorphine/naloxone film <sup>QL</sup><br>Zubsolv <sup>® QL</sup> |                              |

Effective July 20, 2022